



Brief Report

# Effects of Chronic Sleep Restriction on Transcriptional Sirtuin 1 Signaling Regulation in Male Mice White Adipose Tissue

Marco Rendine <sup>1,2</sup>, Paolo Cocci <sup>1</sup>, Luisa de Vivo <sup>3</sup>, Michele Bellesi <sup>1,4</sup>  and Francesco Alessandro Palermo <sup>1,\*</sup>

<sup>1</sup> School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy; marco.rendine@unimi.it (M.R.); paolo.cocci@unicam.it (P.C.); michele.bellesi@unicam.it (M.B.)

<sup>2</sup> Department of Food, Environmental and Nutritional Sciences (DeFENS), Università degli Studi di Milano, 20133 Milan, Italy

<sup>3</sup> School of Pharmacy, University of Camerino, 62032 Camerino, Italy; luisa.devivo@unicam.it

<sup>4</sup> School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1QU, UK

\* Correspondence: francesco.palermo@unicam.it; Tel.: +39-0737-404920

**Abstract:** Chronic sleep restriction (CSR) is a prevalent issue in modern society that is associated with several pathological states, ranging from neuropsychiatric to metabolic diseases. Despite its known impact on metabolism, the specific effects of CSR on the molecular mechanisms involved in maintaining metabolic homeostasis at the level of white adipose tissue (WAT) remain poorly understood. Therefore, this study aimed to investigate the influence of CSR on sirtuin 1 (SIRT1) and the peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) signaling pathway in the WAT of young male mice. Both genes interact with specific targets involved in multiple metabolic processes, including adipocyte differentiation, browning, and lipid metabolism. The quantitative PCR (qPCR) results demonstrated a significant upregulation of SIRT-1 and some of its target genes associated with the transcriptional regulation of lipid homeostasis (i.e., PPAR $\alpha$ , PPAR $\gamma$ , PGC-1 $\alpha$ , and SREBF) and adipose tissue development (i.e., leptin, adiponectin) in CSR mice. On the contrary, DNA-binding transcription factors (i.e., CEBP- $\beta$  and C-myc), which play a pivotal function during the adipogenesis process, were found to be down-regulated. Our results also suggest that the induction of SIRT1-dependent molecular pathways prevents weight gain. Overall, these findings offer new, valuable insights into the molecular adaptations of WAT to CSR, in order to support increased energy demand due to sleep loss.

**Keywords:** sleep restriction; SIRT1 expression; lipid homeostasis



**Citation:** Rendine, M.; Cocci, P.; de Vivo, L.; Bellesi, M.; Palermo, F.A. Effects of Chronic Sleep Restriction on Transcriptional Sirtuin 1 Signaling Regulation in Male Mice White Adipose Tissue. *Curr. Issues Mol. Biol.* **2024**, *46*, 2144–2154. <https://doi.org/10.3390/cimb46030138>

Academic Editor: Jui-Hung Yen

Received: 8 February 2024

Revised: 1 March 2024

Accepted: 5 March 2024

Published: 7 March 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

White adipose tissue (WAT) is one of the most important organs involved in the regulation of metabolic homeostasis. WAT influences both endocrine homeostasis and immune system function by secreting several adipokines, such as leptin [1], adiponectin [2], TNF $\alpha$  [3], and resistin [4], among many others [5]. In addition, WAT adipocytes show significant phenotypic plasticity, as demonstrated by their involvement in the browning phenomenon (i.e., a switch from white to beige-like adipocytes) [6]. WAT transcriptional signaling is finely orchestrated by networks of transcription factors that regulate the expression of several target genes. In this regard, sirtuin 1 (SIRT1) is a NAD<sup>+</sup>-dependent deacetylase involved in regulating key metabolic pathways in adipocytes [7,8]. The SIRT1-related molecular network includes several fatty acid sensors, such as peroxisome proliferator-activated receptors (PPARs) [9], and transcription factor coregulators, such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 $\alpha$ ) and a PR domain containing 16 (PRDM16) [7]. It has recently been reported that the interplay between PPAR $\gamma$  and SIRT1 seems to be critical for WAT browning [10]. This phenotypic change is likely to be protective against obesity-associated metabolic disorders [11]. The importance of SIRT1 signaling in WAT is supported by several in vitro and in vivo studies [10,12]. In

fact, the deregulation of the SIRT1-mediated pathway is closely associated with a range of metabolic alterations, as observed in a SIRT1 adipose-specific knockdown mouse model which resulted in fat accumulation, alterations in glucose and lipid metabolism, as well as impaired insulin sensitivity, and the development of obesity [12]. There is also evidence that SIRT1 has an anti-inflammatory effect on WAT by inhibiting the expression of inflammatory response genes [13,14]. One of the environmental factors that can modulate metabolism and has been linked to increased risks of developing obesity is sleep deprivation. Many studies described an inverse or U-shaped relationship between sleep duration and weight gain [15–17], with sleep deprivation being associated with increased hunger and appetite, through affecting the leptin and ghrelin signaling pathways [18], an increased intake of caloric food [19,20], and a higher Body Mass Index (BMI) [16]. In addition to increasing food intake, sleep restriction is responsible for causing endocrine and metabolic alterations, including decreased glucose tolerance, decreased insulin sensitivity [21,22], and increased evening concentrations of cortisol [23,24]. In addition, epidemiologic data correlate short sleep habits with the onset of metabolic-related disorders such as obesity and type 2 diabetes Mellitus, T2DM [25,26]. It has also been suggested that sleep restriction may be an important regulator of energy metabolism in peripheral tissues by increasing insulin resistance in human adipocytes [27]. However, to date, very little is known about the effect of sleep loss on WAT metabolic homeostasis, especially at the molecular level. Given the progressive decrease in sleep time and the concomitant marked increase in obesity witnessed in the last decades in modern societies [15–17], investigating the causal link and the physiological mechanisms involved in sleep loss and WAT metabolism could lead to the identification of new strategies to ameliorate health. Here, we investigated whether chronic sleep restriction (CSR), a condition of prolonged short sleep, affects the transcriptional regulation of SIRT1 signaling in mice WAT. Gene expression analysis was used to identify key SIRT1-regulated metabolic pathways in WAT. The data demonstrated that CSR increased the expression levels of SIRT1 and some of its transcriptional targets (i.e., PPARs, PGC-1A, and sterol regulatory element-binding transcription factor 1/2-SREBF) involved in the lipid metabolism and mitochondrial functions of adipocytes. These data provide new insights into how SIRT1 signaling regulates adipogenic pathways in sleep-restricted mice.

## 2. Materials and Methods

### 2.1. Animals


Male C57BL/6J mice (14 weeks old) were used for the experiment. Mice were housed in groups of two in environmentally controlled cages for the duration of the experiment. Environmental conditions were as follows: 12 h light/dark cycle, light on at 8:00 p.m.; temperature of  $24 \pm 1$  °C; food (standard laboratory chow, VWR International, LLC, Radnor, PA, USA, Cat N. 470105-576) and water available ad libitum and replaced daily at 9:00 a.m. The body weights of mice were measured before and after experimental conditions. The food intake of mice was measured daily by recording the amount of chow consumed per cage. All the experiments were performed according to the local Institutional Animal care and Use Committee and the European Communities Council Directives (2010/63/EU, protocol P5E96A446) and complied with the 3Rs Australian Code for the care and use of animals for scientific purposes (Replacement of animals with alternatives wherever possible, Reduction in number of animals used, and Refinement of experimental conditions and procedures to minimize the harm to animals) [28].

### 2.2. Experimental Conditions

The experimental design is summarized in Figure 1. Mice were weight-balanced and divided into two experimental groups: (1) chronic sleep-restricted (CSR) group ( $n = 8$ ), with a mean body weight of 23.9 g (95% CI: 23.1, 24.8). In this group, mice were sleep-restricted for 14 days (24/24 h) using an automated sleep deprivation chamber (Pinnacle Technology Inc., Lawrence, KS, USA). The effectiveness of this automated sleep deprivation method has been proved in previous experiments using EEG recording in rodents [29,30]. The

procedure consists of a rotating bar placed at a short distance above the cage floor, lightly nudging the animal from sleep and encouraging low levels of activity until the animal maintains wakefulness on its own. The rotating bar was set counterclockwise, at a velocity of 2 rpm (one turn each 30 s). (2) Control (CTR) group (n = 8), with a mean body weight of 22.9 g (95% CI: 21.9, 24.0). In this group, mice were placed in the same sleep deprivation chambers and allowed to sleep undisturbed, except for 3 h/day (during the dark period, when mice are usually awake), during which the bar rotation was activated to expose the mice of this group to the experience of the bar movement and the stress associated with it. Animal behavior was assessed daily by two different operators through direct visual observation, aiming to minimize subjective bias. After 14 days, all mice were sacrificed between 9:00 and 11:00 a.m. to maintain the time of tissue collection within the same 2 h time window for all experimental groups.

## Experimental Design



**Figure 1.** Experimental design. Young adult mice were divided into two groups: Chronic sleep restriction (CSR) and Control group (CTR). Mice were exposed to either CSR or 3 h bar movement for 14 days, then tissue was collected for molecular analysis.

### 2.3. WAT Collection

All mice were deeply anesthetized with isoflurane 3%. Mice were sacrificed by cervical dislocation, immediately immersed in a freezing 2-methylbutane solution for a few seconds and dissected for WAT collection. To access visceral organs, the central skin near the genital organs was elevated and a small incision was performed. Then, the scissor was put horizontally into the opened hole, allowing the cutting of the abdominal muscle along the linea alba (for ~4 cm, depending on the mouse size) from the genitals to the rib cage. Consistently, WAT was collected in the same specific area for all mice. The fat used in this study was perigonadal fat (PGF), localized around the reproductive organs. PGF was collected by separating it from surrounding structures (epididymis, the testis, and the ductus deferens). All samples were immediately frozen in dry ice and subsequently stored in a  $-80^{\circ}\text{C}$  freezer for later analysis.

### 2.4. Molecular Analyses

Total RNA was extracted from 50 mg of WAT using 0.5 mL QIAzol<sup>®</sup> Lysis Reagent (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions (QIAzol<sup>®</sup> Lysis Reagent, QIAGEN<sup>®</sup> Sample & Assay Technologies). RNA concentration and purity were assessed spectrophotometrically at an absorbance of 260/280 nm, and the integrity was confirmed by electrophoresis through 1% agarose gels stained with ethidium bromide. The complementary DNA (cDNA) was synthesized from 2  $\mu\text{g}$  of total RNA in 20  $\mu\text{L}$  of total volume reaction using 4  $\mu\text{L}$  of 5X All-In-One RT MasterMix (abm, Richmond, BC, Canada) according to the manufacturer's instructions (abm<sup>®</sup>, Cat. No. G592). The optimized 5X RT MasterMix contains abm's proprietary OneScript<sup>®</sup> Hot Reverse Transcriptase, RNaseOFF

Ribonuclease Inhibitor, temperature-sensitive DNase, dNTPs, and a finely balanced ratio of Oligo (dT)s and Random Primers. The mixture was incubated at 37 °C for 15 min, followed by 45 °C for 60 min. The cDNA synthesis reaction was stopped by heating at 85 °C for 2 min. SYBR green-based real-time PCR (q-PCR) was used to evaluate expression profiles of PPAR $\gamma$ , PPAR $\alpha$ , SIRT-1, LEPT, PGC-1A, PRDM16, C-Myc, SREBF, CEBP, UCP-1, and ADIPONECTIN target genes. The most stable housekeeping gene, Glucose-6-phosphate dehydrogenase (G6PDH), was used as a reference gene for the qPCR analysis [31]. All the primer sequences are reported in Table 1. The expression of individual gene targets was analyzed using the ABI 7300 Real-Time PCR System (Applied Biosystems Inc., Waltham, MA, USA). All reactions were prepared in 20  $\mu$ L of total volume using BlasTaq™ 2X qPCR MasterMix according to the manufacturer's instructions (abm, Richmond, BC, Canada). Briefly, the reaction included 10  $\mu$ L BlasTaq™ 2X qPCR MM (Abm®, Richmond, BC, Canada), 10  $\mu$ mol L<sup>-1</sup> each of forward and reverse primers, 1  $\mu$ L cDNA template, and sterile distilled water (abm®, Richmond, BC, Canada). Thermocycling for all reactions was for 3 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and of 60 s at 60 °C. Fluorescence was monitored at the end of every cycle. Melting curve analysis was performed to confirm the presence of a single amplicon of interest. Results were calculated using the relative 2<sup>- $\Delta\Delta$ Ct</sup> method [32] and means of mRNA levels were expressed with respect to control mice  $\pm$  standard deviation (SD).

**Table 1.** Primer sequences (5'-3') used for qPCR analysis.

Gene	Primer Sequence (5'-3')	GenBank	Reference
PPAR $\gamma$	ATGGAGCCTAAGTTTGAGTTTGCT GGATGTCCTCGATGGGCTTCA	XM_006505737.5	[33]
PPAR $\alpha$	CACCCTCTCTCCAGCTTCCA GCCTTGTCCTCCACATATTCG	XM_011245516.4	[34]
SIRT-1	CGATGACAGAACGTCACACG TCGAGGATCGGTGCCAATCA	NM_019812.3	[35]
LEPT	GACATTTACACAGGCAGTCCG GCAAGCTGGTGAGGATCTGT	NM_008493.3	[31]
ADIPONECTIN	GAGAAGGGAGACGCAGGTGT GCTGAATGCTGAGTGATACATGTAAG	XM_032899235.1	[31]
SREBF	GAACAGACACTGGCCGAGAT GAGGCCAGAGAAGCAGAAGAG	NM_011480.4	[36]
CEBP- $\beta$	ACCGGGTTTCGGGACTTGA GTTGCGTAGTCCCGTGCCA	X62600.1	[37]
C-Myc	GCCACGTCTCCACACATCAG TGGTGCATTTTCGGTTGTTG	XM_021216459.1	[38]
PRDM16	CACGGTGAAGCCATTCATATGCG AGGTTGGAGAACTGCGTGTAGG	XM_006539171.5	[35]
UCP-1	GCCATCTGCATGGGATCAAACC TCGTCCCTTCCAAAGTGTGAC	NM_009463.3	[35]
PGC-1 $\alpha$	CTCCAGCCTGACGGCACCC GCAGGGACGTCTTTGTGGCT	NM_001330751.2	[39]
G6PDH	ATTGACCACTACCTGGGCAA GAGATACTTCAACACTTTGACCT	XM_021153829.2	[31]

## 2.5. STRING Network Visualization

A cluster analysis of the genes selected in the present study was performed using the K-means clustering method in STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) [40,41], only including interactions with a confidence score higher than 0.7. The STRING v11.5 web resource [42] is a database which gives an association score for interacting proteins, which is calculated using various parameters such as neighborhood


score, fusion, co-occurrence, homology, co-expression, experimental, database, and text mining score [43]. Recently, STRING v11.5 has been also successfully applied to identify gene interaction networks [41,44]. To simplify the dense network and to obtain a better visual representation and comprehension of the interactions, the resulting groups were manually separated.

### 2.6. Statistical Analysis

q-PCR results were expressed as the normalized fold change corrected for G6PDH and with respect to the control group ( $2^{-\Delta\Delta Ct}$  method). Data were first examined for their fit to a normal distribution and homogeneity of variance using Kolmogorov–Smirnov and Levene median tests. Student's *t*-test was used to determine statistical differences between CSR and Control group. All statistical analyses were performed with GraphPad Prism 8.0 (GraphPad Software, Inc., San Diego, CA, USA).

## 3. Results

The expression levels of SIRT1 were significantly increased in CSR mice with respect to the control animals (Figure 2A,  $p < 0.001$ ). Similarly, the signaling pathway downstream from activated SIRT1 (i.e., PPAR $\alpha$ , PPAR $\gamma$ , PGC-1 $\alpha$ , LEPT, ADIPONECTIN, and SREBF) was significantly up-regulated by sleep restriction (Figure 2A,  $p < 0.05$ ). On the contrary, CEBP- $\beta$  and C-myc were down-regulated in sleep-restricted mice (Figure 2A,  $p < 0.05$ ). Both PRDM16 and UCP-1 did not show any significant difference in mRNA levels between the experimental groups (Figure 2A). The K-means clustering analysis in STRING identified four main clusters (Figure 2B). All genes within and between each cluster are strongly interconnected, reflecting a high degree of functional association, and suggesting an interplay among the numerous pathways related to the gene network. In this regard, we identified genes that (1) are involved in the transcriptional regulation of lipid homeostasis (red group), (2) are defined as DNA-binding transcription factors during the adipogenesis process (light blue group), and (3) act as regulators for adipose tissue development (green group) (Figure 2B). Our results also showed that the body weights of CSR mice remained almost unchanged after 14 days of treatment, while the body weights of control mice were found to be significantly increased at the end of the experiment (Figure 2C,  $p < 0.001$ ). Regarding food consumption, no significant differences were found between groups, with a mean food intake of  $3.5 \pm 0.3$  g/day in CTR mice and  $4.2 \pm 1.1$  g/day in CSR mice.



**Figure 2.** Effects of chronic sleep restriction (CSR) on mRNA expression of white adipose tissue (WAT)-related genes (A) and body weights (C). Sirtuin-1 (SIRT1); peroxisome proliferator-activated



receptor gamma (PPAR $\gamma$ ); peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ); sterol regulatory element-binding transcription factor 1/2 (SREBF); peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 $\alpha$ ); leptin (LEPT); CCAAT/enhancer-binding protein beta (CEBP- $\beta$ ); Myc (C-Myc); PR domain containing 16 (PRDM16); Uncoupling Protein 1 (UCP1); adiponectin. Gene expression is shown as fold changes relative to the control group. Data are means  $\pm$  95% C.I. (n = 8). \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ , \*\*\*\*  $p < 0.0001$ . Clustered gene association network using STRING v11.5 (B). The solid and dotted lines indicate connections within the same and different clusters, respectively.

#### 4. Discussion

In this study, we investigated the effects of CSR on SIRT1-dependent molecular pathways in the WAT of mice models. Our findings are consistent with the role of SIRT1 activation in adipose tissue signaling as previously suggested by different studies and well described by Boutant and Cantó [7]. Indeed, the up-regulation of SIRT1 was found to decrease the mRNA levels of key WAT transcription factors and up-regulate those of brown adipose tissue (BAT) genes. Importantly, the genes whose expression is induced by SIRT1 activation include those involved in mitochondrial biogenesis, such as PGC-1 $\alpha$ , and fatty acid oxidation, such as PPAR $\alpha$  [9,45]. Majeed et al. [10] reported that PGC-1 $\alpha$  expression levels were promoted by SIRT1, as demonstrated using SIRT1-depleted adipocyte models which, in turn, showed a reduced mitochondrial mass and respiratory capacity. On the other hand, the activation of PPAR $\alpha$  is pivotal in regulating lipid metabolism and promoting fatty acid oxidation [45]. The SIRT1:PPAR $\alpha$  interaction was protective in cardiac hypertrophy [46] and the deregulation of its related signaling pathway was associated with reduced fatty acid oxidation in the liver [47]. Interestingly, the CSR-induced up-regulation of PPAR $\alpha$  paired with that of SREBF. As previously demonstrated, SREBF1 overexpression in 3T3-L1 adipocytes promoted fatty acid metabolism and resulted in the production of lipids that work as PPAR $\gamma$  ligands [48,49]. Therefore, these findings could explain, at least in part, the increase in PPAR $\gamma$  expression observed in our study. There is, indeed, evidence that, in WAT, SIRT1 usually acts as a PPAR $\gamma$  repressor rather than an inducer [50]. This effect is most likely due to a SIRT1-dependent deacetylation of PPAR $\gamma$  that subsequently causes the recruitment of PRDM16, a transcriptional co-regulator of the BAT genetic program. Importantly, the SIRT1-dependent deacetylation of PPAR $\gamma$  is responsible for UCP-1 induction in WAT [51]. However, we found no change in UCP-1 nor in PDRM16 expression, which could indicate unaffected acetylation levels of PPAR $\gamma$  in WAT. Other studies found increased UCP mRNA and protein levels in the BAT and muscles of chronic sleep-restricted rats, suggesting the increased energy expenditure associated with prolonged sleep loss [52,53].

Our study also indicates that sleep restriction significantly increased the expression of the leptin and adiponectin adipokines in the CSR group with respect to the control mice. From a molecular point of view, it is possible that a SIRT1-mediated increase in CEBP- $\alpha$  transcriptional activity is responsible for the induction of the leptin gene in response to CSR. The stimulation of leptin transcription was previously found to be SIRT1-dependent in preadipocytes supplemented with the NAD<sup>+</sup> booster, nicotinamide mononucleotide (NMN) [10]. In addition, leptin expression is highly correlated with PPAR $\gamma$  expression, which was also increased in CSR mice [54]. However, in the literature, there are conflicting results regarding leptin circulation in sleep curtailment, with its levels found to be both reduced [55–57] and elevated [58–61]. These discrepancies may be related to the duration and quality of sleep disturbances applied. Qiao and Shao [62] have demonstrated that SIRT1 can also be involved in up-regulating adiponectin expression by inducing Foxo1 transactivation activity. We can thus speculate that, with CSR, SIRT1 expression is induced, which leads to the mobilization of fatty acids in WAT and the increased transcription of adiponectin. Adiponectin, in turn, enhances insulin sensitivity, further improving fatty acid oxidation [63].

Overall, our data suggest the presence of functional interactions among SIRT1, PPAR $\alpha$ , SREBF, and PGC-1 $\alpha$  that result in reduced fat accumulation and enhanced fat consumption, probably due to the stimulation of the adipose thermogenic capacity. Together with leptin, all these genes act as metabolic regulators whose expression patterns are sensitive to CSR in a SIRT1-dependent manner. The CSR-induced downregulation of genes associated with the adipogenic pathway (i.e., CEBP- $\beta$  and C-Myc) is also consistent with the reduction in fat accumulation. Earlier evidence has shown that adipogenesis, as well as adipocyte differentiation, are driven by two subsequent waves of transcription factor activation during which CEBP- $\beta$  has a pivotal function [64,65]. CEBP- $\beta$  is a well-known early mediator of adipocyte differentiation and is involved in the activation of several targets, including PPAR $\gamma$ , which, in turn, mediate adipogenic differentiation [66]. Interestingly, CEBP- $\beta$  shows polylysine acetylation, which may be a deacetylation target of SIRT1 [67]. Consequently, SIRT1-dependent deacetylation alters CEBP- $\beta$  function as a transcription factor in adipocytes. In line with this, SIRT1 was shown to inhibit C-Myc signaling, as demonstrated using SIRT1-silenced preadipocytes [68]. The SIRT1-mediated deacetylation of C-Myc resulted in reduced preadipocyte hyperplasia, lipid accumulation, and inflammation [68]. In addition, Tóth et al. [69] suggested that C-Myc could participate in the regulation of the adipocyte–thermogenic function by modulating UCP1 gene expression. Overall, the CSR-induced overexpression of SIRT1 matches the repression of both CEBP- $\beta$  and C-Myc.

Chronic sleep restriction in rodents is known to cause a cluster of syndromes first described by Rechtschaffen and Bergmann [70] and that include hyperphagia, weight loss, elevated energy expenditure, increased plasma catecholamines, hypothyroidism, reduction in core temperature, deterioration in physical appearance [71], reduced levels of anabolic hormones [72], and declines in the integrity of the immune system [73]. Reduced weight gain occurs consistently, despite unchanged or increased levels of food consumption [52,74,75]. Accordingly, our results suggest that the induction of SIRT1-dependent molecular pathways prevents weight gain. Indeed, in the present work, CSR causes trouble in gaining weight, despite food intake remaining unchanged. Our findings also suggest that, in addition to the increased energy expenditure associated with sleep restriction, the overexpression of SIRT1 signaling could be involved in regulating lipid metabolism, mostly by inducing a decrease in fat accumulation leading to a new energy homeostasis. As a whole, the obtained gene network highlights the crucial role of SIRT1-dependent molecular pathways in mediating the metabolic remodeling of adipose tissue induced by CSR.

## 5. Conclusions

Altogether, our results indicate that CSR induces the SIRT1-mediated metabolic remodeling of WAT. The overexpression of SIRT1 decreases lipid accumulation, probably by inducing fat oxidation and increasing adaptive thermogenesis. However, further studies are needed to characterize the temporal dynamics of thermogenic gene expression and the long-term effects of WAT adaptation to CSR.

**Author Contributions:** Conceptualization, F.A.P., M.R. and M.B.; methodology, M.B., F.A.P. and P.C.; software, F.A.P., P.C. and M.R.; validation, F.A.P.; formal analysis, M.R. and P.C.; investigation, M.R. and P.C.; resources, M.B., L.d.V. and F.A.P.; data curation, F.A.P. and P.C.; writing—original draft preparation, M.R.; writing—review and editing, F.A.P. and M.B.; visualization, F.A.P.; supervision, M.B., L.d.V. and F.A.P.; project administration, F.A.P. and M.B.; funding acquisition, F.A.P. and M.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** All the experiments were performed according to the local Institutional Animal Care and Use Committee and the European Communities Council Directives (2010/63/EU, protocol P5E96A446).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Maffei, M.; Halaas, J.; Ravussin, E.; Pratley, R.E.; Lee, G.H.; Zhang, Y.; Fei, H.; Kim, S.; Lallone, R.; Ranganathan, S. Leptin Levels in Human and Rodent: Measurement of Plasma Leptin and Ob RNA in Obese and Weight-Reduced Subjects. *Nat. Med.* **1995**, *1*, 1155–1161. [[CrossRef](#)] [[PubMed](#)]
2. Scherer, P.E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H.F. A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes. *J. Biol. Chem.* **1995**, *270*, 26746–26749. [[CrossRef](#)] [[PubMed](#)]
3. Hotamisligil, G.S.; Arner, P.; Atkinson, R.L.; Spiegelman, B.M. Differential Regulation of the P80 Tumor Necrosis Factor Receptor in Human Obesity and Insulin Resistance. *Diabetes* **1997**, *46*, 451–455. [[CrossRef](#)] [[PubMed](#)]
4. Steppan, C.M.; Bailey, S.T.; Bhat, S.; Brown, E.J.; Banerjee, R.R.; Wright, C.M.; Patel, H.R.; Ahima, R.S.; Lazar, M.A. The Hormone Resistin Links Obesity to Diabetes. *Nature* **2001**, *409*, 307–312. [[CrossRef](#)] [[PubMed](#)]
5. Rodríguez, A.; Ezquerro, S.; Méndez-Giménez, L.; Becerril, S.; Frühbeck, G. Revisiting the Adipocyte: A Model for Integration of Cytokine Signaling in the Regulation of Energy Metabolism. *Am. J. Physiol. Endocrinol. Metab.* **2015**, *309*, E691–E714. [[CrossRef](#)] [[PubMed](#)]
6. Kuryłowicz, A.; Puzianowska-Kuźnicka, M. Induction of Adipose Tissue Browning as a Strategy to Combat Obesity. *Int. J. Mol. Sci.* **2020**, *21*, 6241. [[CrossRef](#)]
7. Boutant, M.; Cantó, C. SIRT1 Metabolic Actions: Integrating Recent Advances from Mouse Models. *Mol. Metab.* **2014**, *3*, 5–18. [[CrossRef](#)]
8. Seale, P.; Kajimura, S.; Yang, W.; Chin, S.; Rohas, L.M.; Uldry, M.; Tavernier, G.; Langin, D.; Spiegelman, B.M. Transcriptional Control of Brown Fat Determination by PRDM16. *Cell Metab.* **2007**, *6*, 38–54. [[CrossRef](#)]
9. Guan, Y.; Zhang, Y.; Breyer, M.D. The Role of PPARs in the Transcriptional Control of Cellular Processes. *Drug News Perspect.* **2002**, *15*, 147–154. [[CrossRef](#)]
10. Majeed, Y.; Halabi, N.; Madani, A.Y.; Engelke, R.; Bhagwat, A.M.; Abdesselem, H.; Agha, M.V.; Vakayil, M.; Courjaret, R.; Goswami, N.; et al. SIRT1 Promotes Lipid Metabolism and Mitochondrial Biogenesis in Adipocytes and Coordinates Adipogenesis by Targeting Key Enzymatic Pathways. *Sci. Rep.* **2021**, *11*, 8177. [[CrossRef](#)]
11. Smorlesi, A.; Frontini, A.; Giordano, A.; Cinti, S. The Adipose Organ: White-Brown Adipocyte Plasticity and Metabolic Inflammation: Adipocyte Plasticity and Adipose Organ. *Obes. Rev.* **2012**, *13* (Suppl. S2), 83–96. [[CrossRef](#)]
12. Li, F.; Li, H.; Jin, X.; Zhang, Y.; Kang, X.; Zhang, Z.; Xu, M.; Qian, Z.; Ma, Z.; Gao, X.; et al. Adipose-Specific Knockdown of Sirt1 Results in Obesity and Insulin Resistance by Promoting Exosomes Release. *Cell Cycle* **2019**, *18*, 2067–2082. [[CrossRef](#)] [[PubMed](#)]
13. Chalkiadaki, A.; Guarente, L. High-Fat Diet Triggers Inflammation-Induced Cleavage of SIRT1 in Adipose Tissue to Promote Metabolic Dysfunction. *Cell Metab.* **2012**, *16*, 180–188. [[CrossRef](#)]
14. Yoshizaki, T.; Milne, J.C.; Imamura, T.; Schenk, S.; Sonoda, N.; Babendure, J.L.; Lu, J.-C.; Smith, J.J.; Jirousek, M.R.; Olefsky, J.M. SIRT1 Exerts Anti-Inflammatory Effects and Improves Insulin Sensitivity in Adipocytes. *Mol. Cell. Biol.* **2009**, *29*, 1363–1374. [[CrossRef](#)] [[PubMed](#)]
15. Cappuccio, F.P.; Taggart, F.M.; Kandala, N.-B.; Currie, A.; Peile, E.; Stranges, S.; Miller, M.A. Meta-Analysis of Short Sleep Duration and Obesity in Children and Adults. *Sleep* **2008**, *31*, 619–626. [[CrossRef](#)]
16. Miller, M.A.; Kruisbrink, M.; Wallace, J.; Ji, C.; Cappuccio, F.P. Sleep Duration and Incidence of Obesity in Infants, Children, and Adolescents: A Systematic Review and Meta-Analysis of Prospective Studies. *Sleep* **2018**, *41*, zsy018. [[CrossRef](#)]
17. Wu, Y.; Zhai, L.; Zhang, D. Sleep Duration and Obesity among Adults: A Meta-Analysis of Prospective Studies. *Sleep Med.* **2014**, *15*, 1456–1462. [[CrossRef](#)]
18. Spiegel, K.; Leproult, R.; L'hermite-Balériaux, M.; Copinschi, G.; Penev, P.D.; Van Cauter, E. Leptin Levels Are Dependent on Sleep Duration: Relationships with Sympathovagal Balance, Carbohydrate Regulation, Cortisol, and Thyrotropin. *J. Clin. Endocrinol. Metab.* **2004**, *89*, 5762–5771. [[CrossRef](#)]
19. Spaeth, A.M.; Dinges, D.F.; Goel, N. Sex and Race Differences in Caloric Intake during Sleep Restriction in Healthy Adults. *Am. J. Clin. Nutr.* **2014**, *100*, 559–566. [[CrossRef](#)]
20. Zhu, B.; Shi, C.; Park, C.G.; Zhao, X.; Reutrakul, S. Effects of Sleep Restriction on Metabolism-Related Parameters in Healthy Adults: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials. *Sleep Med. Rev.* **2019**, *45*, 18–30. [[CrossRef](#)]
21. Rao, M.N.; Neylan, T.C.; Grunfeld, C.; Mulligan, K.; Schambelan, M.; Schwarz, J.-M. Subchronic Sleep Restriction Causes Tissue-Specific Insulin Resistance. *J. Clin. Endocrinol. Metab.* **2015**, *100*, 1664–1671. [[CrossRef](#)] [[PubMed](#)]
22. Nedeltcheva, A.V.; Kessler, L.; Imperial, J.; Penev, P.D. Exposure to Recurrent Sleep Restriction in the Setting of High Caloric Intake and Physical Inactivity Results in Increased Insulin Resistance and Reduced Glucose Tolerance. *J. Clin. Endocrinol. Metab.* **2009**, *94*, 3242–3250. [[CrossRef](#)] [[PubMed](#)]



23. Omisade, A.; Buxton, O.M.; Rusak, B. Impact of Acute Sleep Restriction on Cortisol and Leptin Levels in Young Women. *Physiol. Behav.* **2010**, *99*, 651–656. [[CrossRef](#)] [[PubMed](#)]
24. Guyon, A.; Morselli, L.L.; Balbo, M.L.; Tasali, E.; Leproult, R.; L'Hermite-Balériaux, M.; Van Cauter, E.; Spiegel, K. Effects of Insufficient Sleep on Pituitary-Adrenocortical Response to CRH Stimulation in Healthy Men. *Sleep* **2017**, *40*, zsx064. [[CrossRef](#)] [[PubMed](#)]
25. Itani, O.; Jike, M.; Watanabe, N.; Kaneita, Y. Short Sleep Duration and Health Outcomes: A Systematic Review, Meta-Analysis, and Meta-Regression. *Sleep Med.* **2017**, *32*, 246–256. [[CrossRef](#)] [[PubMed](#)]
26. Inoue, K.; Semba, E.; Yamakawa, T.; Terauchi, Y. Associations of Impaired Glucose Tolerance and Sleep Disorders with Mortality among the US General Population. *BMJ Open Diabetes Res. Care* **2021**, *9*, e002047. [[CrossRef](#)]
27. Broussard, J.L.; Ehrmann, D.A.; Van Cauter, E.; Tasali, E.; Brady, M.J. Impaired Insulin Signaling in Human Adipocytes after Experimental Sleep Restriction: A Randomized, Crossover Study: A Randomized, Crossover Study. *Ann. Intern. Med.* **2012**, *157*, 549–557. [[CrossRef](#)]
28. Schuppli, C.A.; Fraser, D. The Interpretation and Application of the Three Rs by Animal Ethics Committee Members. *Altern. Lab. Anim.* **2005**, *33*, 487–500. [[CrossRef](#)]
29. Fenzl, T.; Romanowski, C.P.N.; Flachsamm, C.; Honsberg, K.; Boll, E.; Hoehne, A.; Kimura, M. Fully Automated Sleep Deprivation in Mice as a Tool in Sleep Research. *J. Neurosci. Methods* **2007**, *166*, 229–235. [[CrossRef](#)]
30. Bergmann, B.M.; Kushida, C.A.; Everson, C.A.; Gilliland, M.A.; Obermeyer, W.; Rechtschaffen, A. Sleep Deprivation in the Rat: II. *Methodol. Sleep* **1989**, *12*, 5–12. [[CrossRef](#)]
31. Barbu, A.; Hedlund, G.P.; Lind, J.; Carlsson, C. Pref-1 and Adipokine Expression in Adipose Tissues of GK and Zucker Rats. *Mol. Cell. Endocrinol.* **2009**, *299*, 163–171. [[CrossRef](#)]
32. Livak, K.J.; Schmittgen, T.D. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2<sup>(-Delta Delta C(T))</sup> Method. *Methods* **2001**, *25*, 402–408. [[CrossRef](#)] [[PubMed](#)]
33. Mandard, S.; Zandbergen, F.; Tan, N.S.; Escher, P.; Patsouris, D.; Koenig, W.; Kleemann, R.; Bakker, A.; Veenman, F.; Wahli, W.; et al. The Direct Peroxisome Proliferator-Activated Receptor Target Fasting-Induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment. *J. Biol. Chem.* **2004**, *279*, 34411–34420. [[CrossRef](#)] [[PubMed](#)]
34. Song, L.; Qu, D.; Zhang, Q.; Jiang, J.; Zhou, H.; Jiang, R.; Li, Y.; Zhang, Y.; Yan, H. Corrigendum: Phytosterol Esters Attenuate Hepatic Steatosis in Rats with Non-Alcoholic Fatty Liver Disease Rats Fed a High-Fat Diet. *Sci. Rep.* **2017**, *7*, 46884. [[CrossRef](#)] [[PubMed](#)]
35. Nøhr, M.; Bobba, N.; Richelsen, B.; Lund, S.; Pedersen, S. Inflammation Downregulates UCP1 Expression in Brown Adipocytes Potentially via SIRT1 and DBC1 Interaction. *Int. J. Mol. Sci.* **2017**, *18*, 1006. [[CrossRef](#)] [[PubMed](#)]
36. Volat, F.E.; Pointud, J.-C.; Pastel, E.; Morio, B.; Sion, B.; Hamard, G.; Guichardant, M.; Colas, R.; Lefrançois-Martinez, A.-M.; Martinez, A. Depressed Levels of Prostaglandin F2 $\alpha$  in Mice Lacking Akr1b7 Increase Basal Adiposity and Predispose to Diet-Induced Obesity. *Diabetes* **2012**, *61*, 2796–2806. [[CrossRef](#)] [[PubMed](#)]
37. Matsuda, T.; Kido, Y.; Asahara, S.-I.; Kaisho, T.; Tanaka, T.; Hashimoto, N.; Shigeyama, Y.; Takeda, A.; Inoue, T.; Shibutani, Y.; et al. Ablation of C/EBP $\beta$  Alleviates ER Stress and Pancreatic Beta Cell Failure through the GRP78 Chaperone in Mice. *J. Clin. Invest.* **2010**, *120*, 115–126. [[CrossRef](#)] [[PubMed](#)]
38. Ciribilli, Y.; Borlak, J. Correction: Oncogenomics of c-Myc Transgenic Mice Reveal Novel Regulators of Extracellular Signaling, Angiogenesis and Invasion with Clinical Significance for Human Lung Adenocarcinoma. *Oncotarget* **2018**, *9*, 37269. [[CrossRef](#)]
39. Gao, Q.; Jia, Y.; Yang, G.; Zhang, X.; Boddu, P.C.; Petersen, B.; Narsingam, S.; Zhu, Y.-J.; Thimmapaya, B.; Kanwar, Y.S.; et al. PPAR $\alpha$ -Deficient Ob/Ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation. *Am. J. Pathol.* **2015**, *185*, 1396–1408. [[CrossRef](#)]
40. Poswar, F.d.O.; Farias, L.C.; Fraga, C.A.d.C.; Bambirra, W., Jr.; Brito-Júnior, M.; Sousa-Neto, M.D.; Santos, S.H.S.; de Paula, A.M.B.; D'Angelo, M.F.S.V.; Guimarães, A.L.S. Bioinformatics, Interaction Network Analysis, and Neural Networks to Characterize Gene Expression of Radicular Cyst and Periapical Granuloma. *J. Endod.* **2015**, *41*, 877–883. [[CrossRef](#)]
41. Kumar, R.; Samal, S.K.; Routray, S.; Dash, R.; Dixit, A. Publisher Correction: Identification of Oral Cancer Related Candidate Genes by Integrating Protein-Protein Interactions, Gene Ontology, Pathway Analysis and Immunohistochemistry. *Sci. Rep.* **2018**, *8*, 8356. [[CrossRef](#)]
42. STRING: Functional Protein Association Networks. Available online: <http://string.embl.de> (accessed on 21 November 2023).
43. Korbil, J.O.; Jensen, L.J.; von Mering, C.; Bork, P. Analysis of Genomic Context: Prediction of Functional Associations from Conserved Bidirectionally Transcribed Gene Pairs. *Nat. Biotechnol.* **2004**, *22*, 911–917. [[CrossRef](#)]
44. Doncheva, N.T.; Morris, J.H.; Gorodkin, J.; Jensen, L.J. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *J. Proteome Res.* **2018**, *18*, 623–632. [[CrossRef](#)]
45. Monsalve, F.A.; Pyarasani, R.D.; Delgado-Lopez, F.; Moore-Carrasco, R. Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. *Mediators Inflamm.* **2013**, *2013*, 549627. [[CrossRef](#)]
46. Planavila, A.; Iglesias, R.; Giral, M.; Villarroya, F. Sirt1 Acts in Association with PPAR $\alpha$  to Protect the Heart from Hypertrophy, Metabolic Dysregulation, and Inflammation. *Cardiovasc. Res.* **2011**, *90*, 276–284. [[CrossRef](#)]
47. Purushotham, A.; Schug, T.T.; Xu, Q.; Surapureddi, S.; Guo, X.; Li, X. Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation. *Cell Metab.* **2009**, *9*, 327–338. [[CrossRef](#)]

48. Kim, J.B.; Spiegelman, B.M. ADD1/SREBP1 Promotes Adipocyte Differentiation and Gene Expression Linked to Fatty Acid Metabolism. *Genes Dev.* **1996**, *10*, 1096–1107. [[CrossRef](#)]
49. Kim, J.B.; Wright, H.M.; Wright, M.; Spiegelman, B.M. ADD1/SREBP1 Activates PPAR $\gamma$  through the Production of Endogenous Ligand. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 4333–4337. [[CrossRef](#)] [[PubMed](#)]
50. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M.W.; Guarente, L. Sirt1 Promotes Fat Mobilization in White Adipocytes by Repressing PPAR-Gamma. *Nature* **2004**, *429*, 771–776. [[CrossRef](#)] [[PubMed](#)]
51. Qiang, L.; Wang, L.; Kon, N.; Zhao, W.; Lee, S.; Zhang, Y.; Rosenbaum, M.; Zhao, Y.; Gu, W.; Farmer, S.R.; et al. Brown Remodeling of White Adipose Tissue by SirT1-Dependent Deacetylation of Ppar $\gamma$ . *Cell* **2012**, *150*, 620–632. [[CrossRef](#)] [[PubMed](#)]
52. Koban, M.; Swinson, K.L. Chronic REM-Sleep Deprivation of Rats Elevates Metabolic Rate and Increases UCP1 Gene Expression in Brown Adipose Tissue. *Am. J. Physiol. Endocrinol. Metab.* **2005**, *289*, E68–E74. [[CrossRef](#)]
53. Cirelli, C.; Tononi, G. Uncoupling Proteins and Sleep Deprivation. *Arch. Ital. Biol.* **2004**, *142*, 541–549.
54. Yamauchi, T.; Waki, H.; Kamon, J.; Murakami, K.; Motojima, K.; Kameda, K.; Miki, H.; Kubota, N.; Terauchi, Y.; Tsuchida, A.; et al. Inhibition of RXR and PPAR $\gamma$  Ameliorates Diet-Induced Obesity and Type 2 Diabetes. *J. Clin. Investig.* **2001**, *108*, 1001–1013. [[CrossRef](#)]
55. Taheri, S.; Lin, L.; Austin, D.; Young, T.; Mignot, E. Short Sleep Duration Is Associated with Reduced Leptin, Elevated Ghrelin, and Increased Body Mass Index. *PLoS Med.* **2004**, *1*, e62. [[CrossRef](#)]
56. Chaput, J.-P.; Després, J.-P.; Bouchard, C.; Tremblay, A. Short Sleep Duration Is Associated with Reduced Leptin Levels and Increased Adiposity: Results from the Québec Family Study. *Obesity* **2007**, *15*, 253–261. [[CrossRef](#)]
57. Stern, J.H.; Grant, A.S.; Thomson, C.A.; Tinker, L.; Hale, L.; Brennan, K.M.; Woods, N.F.; Chen, Z. Short Sleep Duration Is Associated with Decreased Serum Leptin, Increased Energy Intake and Decreased Diet Quality in Postmenopausal Women. *Obesity* **2014**, *22*, E55–E61. [[CrossRef](#)]
58. Reynolds, A.C.; Dorrian, J.; Liu, P.Y.; Van Dongen, H.P.A.; Wittert, G.A.; Harmer, L.J.; Banks, S. Impact of Five Nights of Sleep Restriction on Glucose Metabolism, Leptin and Testosterone in Young Adult Men. *PLoS ONE* **2012**, *7*, e41218. [[CrossRef](#)] [[PubMed](#)]
59. Simpson, N.S.; Banks, S.; Dinges, D.F. Sleep Restriction Is Associated with Increased Morning Plasma Leptin Concentrations, Especially in Women. *Biol. Res. Nurs.* **2010**, *12*, 47–53. [[CrossRef](#)] [[PubMed](#)]
60. Hayes, A.L.; Xu, F.; Babineau, D.; Patel, S.R. Sleep Duration and Circulating Adipokine Levels. *Sleep* **2011**, *34*, 147–152. [[CrossRef](#)] [[PubMed](#)]
61. Pejovic, S.; Vgontzas, A.N.; Basta, M.; Tsaousoglou, M.; Zoumakis, E.; Vgontzas, A.; Bixler, E.O.; Chrousos, G.P. Leptin and Hunger Levels in Young Healthy Adults after One Night of Sleep Loss: Leptin after One Night of Sleep Loss. *J. Sleep Res.* **2010**, *19*, 552–558. [[CrossRef](#)] [[PubMed](#)]
62. Qiao, L.; Shao, J. SIRT1 Regulates Adiponectin Gene Expression through Foxo1-C/Enhancer-Binding Protein  $\alpha$  Transcriptional Complex. *J. Biol. Chem.* **2006**, *281*, 39915–39924. [[CrossRef](#)]
63. Kadowaki, T.; Yamauchi, T. Adiponectin and Adiponectin Receptors. *Endocr. Rev.* **2005**, *26*, 439–451. [[CrossRef](#)] [[PubMed](#)]
64. Lefterova, M.I.; Zhang, Y.; Steger, D.J.; Schupp, M.; Schug, J.; Cristancho, A.; Feng, D.; Zhuo, D.; Stoeckert, C.J., Jr.; Liu, X.S.; et al. PPAR $\gamma$  and C/EBP Factors Orchestrate Adipocyte Biology via Adjacent Binding on a Genome-Wide Scale. *Genes Dev.* **2008**, *22*, 2941–2952. [[CrossRef](#)] [[PubMed](#)]
65. Guo, L.; Li, X.; Tang, Q.-Q. Transcriptional Regulation of Adipocyte Differentiation: A Central Role for CCAAT/Enhancer-Binding Protein (C/EBP)  $\beta$ . *J. Biol. Chem.* **2015**, *290*, 755–761. [[CrossRef](#)]
66. Siersbæk, R.; Nielsen, R.; Mandrup, S. Transcriptional Networks and Chromatin Remodeling Controlling Adipogenesis. *Trends Endocrinol. Metab.* **2012**, *23*, 56–64. [[CrossRef](#)] [[PubMed](#)]
67. Ceseña, T.I.; Cardinaux, J.-R.; Kwok, R.; Schwartz, J. CCAAT/Enhancer-Binding Protein (C/EBP) Beta Is Acetylated at Multiple Lysines: Acetylation of C/EBP $\beta$  at Lysine 39 Modulates Its Ability to Activate Transcription. *J. Biol. Chem.* **2007**, *282*, 956–967. [[CrossRef](#)]
68. Abdeselem, H.; Madani, A.; Hani, A.; Al-Noubi, M.; Goswami, N.; Ben Hamidane, H.; Billing, A.M.; Pasquier, J.; Bonkowski, M.S.; Halabi, N.; et al. SIRT1 Limits Adipocyte Hyperplasia through C-Myc Inhibition. *J. Biol. Chem.* **2016**, *291*, 2119–2135. [[CrossRef](#)] [[PubMed](#)]
69. Tóth, B.B.; Barta, Z.; Barta, Á.B.; Fésüs, L. Regulatory Modules of Human Thermogenic Adipocytes: Functional Genomics of Large Cohort and Meta-Analysis Derived Marker-Genes. *BMC Genom.* **2021**, *22*, 886. [[CrossRef](#)]
70. Rechtschaffen, A.; Gilliland, M.A.; Bergmann, B.M.; Winter, J.B. Physiological Correlates of Prolonged Sleep Deprivation in Rats. *Science* **1983**, *221*, 182–184. [[CrossRef](#)]
71. Rechtschaffen, A.; Bergmann, B.M. Sleep Deprivation in the Rat: An Update of the 1989 Paper. *Sleep* **2002**, *25*, 18–24. [[CrossRef](#)]
72. Everson, C.A.; Crowley, W.R. Reductions in Circulating Anabolic Hormones Induced by Sustained Sleep Deprivation in Rats. *Am. J. Physiol. Endocrinol. Metab.* **2004**, *286*, E1060–E1070. [[CrossRef](#)]
73. Everson, C.A.; Toth, L.A. Systemic Bacterial Invasion Induced by Sleep Deprivation. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **2000**, *278*, R905–R916. [[CrossRef](#)] [[PubMed](#)]

74. Barf, R.P.; Van Dijk, G.; Scheurink, A.J.W.; Hoffmann, K.; Novati, A.; Hulshof, H.J.; Fuchs, E.; Meerlo, P. Metabolic Consequences of Chronic Sleep Restriction in Rats: Changes in Body Weight Regulation and Energy Expenditure. *Physiol. Behav.* **2012**, *107*, 322–328. [[CrossRef](#)] [[PubMed](#)]
75. Baud, M.O.; Magistretti, P.J.; Petit, J.-M. Sustained Sleep Fragmentation Affects Brain Temperature, Food Intake and Glucose Tolerance in Mice: Sleep Fragmentation Induces Metabolic Impairments. *J. Sleep Res.* **2013**, *22*, 3–12. [[CrossRef](#)] [[PubMed](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.